Stated Preferences for Attributes of a CYP2C19 Pharmacogenetic Test Among the General Population Presented with a Hypothetical Acute Coronary Syndrome Scenario

Overview of attention for article published in ClinicoEconomics and Outcomes Research: CEOR, March 2020

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 4 Dimensions

Readers on

mendeley: 16 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 4 publications that cite this research output.

4

The most recent citing publications are shown below. View all 4 publications that cite this research output on Dimensions.

Estimating preferences and willingness to pay for pharmacogenetic testing in populations who are medically underserved: a discrete choice experiment

Article in Frontiers in Pharmacology (March 2024)

Assessing the utility of measurement methods applied in economic evaluations of pharmacogenomics applications

Article in Pharmacogenomics (January 2024)

Pharmacogenomic‐based personalized medicine: Multistakeholder perspectives on implementational drivers and barriers in the Canadian healthcare system

Article in Clinical and Translational Science (July 2021)